Most parathyroid tumors will be assessed for parafibromin immunoreactivity if they are atypical, i.e., lack undisputable evidence of malignancy but display worrisome features (be it clinical or histological) often seen in parathyroid carcinomas. Here, CDC73 is linked to parathyroid gland carcinoma.